| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Yue Teh Jang | Chairman | 11.33% | Medeon, Inc. |
| Lin,Rong-Jin | Director | 29.72% | Center Laboratories, Inc. |
| Wu,Zhi-Xiong | Director | 29.72% | Center Laboratories, Inc. |
| Yang,Qi-Hang | Independent Director | 0.00% | |
| Ma,Jia-Ying | Independent Director | 0.00% | |
| Yang,Feng-Xiang | Independent Director | 0.00% | |
| Ye,Jun-Wei | Independent Director | 0.00% |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 101,878 | 292,808 | 196,263 |
| Operating cost | 82,873 | 209,394 | 181,886 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 19,005 | 83,414 | 14,377 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 19,005 | 83,414 | 14,377 |
| Operating expenses | 209,447 | 969,027 | 853,944 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -190,442 | -885,613 | -839,567 |
| Non-operating income and expenses | -414 | 26,970 | -391,121 |
| Net profit (loss) before tax | -190,856 | -858,643 | -1,230,688 |
| Income tax expense (benefits) | -318 | 11,880 | 39,285 |
| Net profit (loss) of ongoing business for the current period | -190,538 | -870,523 | -1,269,973 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -190,538 | -870,523 | -1,269,973 |
| Other comprehensive profit (loss), net | 4,352 | 21,357 | 4,916 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -186,186 | -849,166 | -1,265,057 |
| Net profit (loss) attributable to owners of parent company | -177,993 | -805,512 | -1,204,615 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -12,545 | -65,011 | -65,358 |
| Comprehensive profit (loss) attributable to owners of parent company | -172,448 | -784,971 | -1,199,371 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | -13,738 | -64,195 | -65,686 |
| Basic earnings per share (yuan) | -1 | -8 | -13 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -216,998 | -832,665 | -755,075 |
| Net cash inflows (outflows) from investing activities | 333,897 | 135,208 | 1,595,621 |
| Net cash inflow (outflow) from financing activities | -13,463 | -46,680 | -90,571 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 8,617 | 19,547 | 4,091 |
| Increase (decrease) in cash and cash equivalents in the current period | 112,053 | -724,590 | 754,066 |
| Beginning balance of cash and cash equivalents | 513,374 | 1,237,964 | 483,898 |
| Ending balance of cash and cash equivalents | 625,427 | 513,374 | 1,237,964 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 1,112,113 | 1,317,199 | 2,227,798 |
| Non-current asset | 539,603 | 560,544 | 519,348 |
| Total asset | 1,651,716 | 1,877,743 | 2,747,146 |
| Current liability | 184,443 | 215,642 | 221,755 |
| Non-current liability | 115,840 | 126,198 | 153,896 |
| Total liability | 300,283 | 341,840 | 375,651 |
| share capital | 922,449 | 922,449 | 922,449 |
| Equity - secruity token | - | - | - |
| capital reserve | 1,339,205 | 1,339,205 | 1,340,712 |
| retained earning | -975,159 | -792,938 | 31,246 |
| Other equity | 62,270 | 56,725 | 36,184 |
| Treasury stock | -5,249 | -5,249 | -10,603 |
| Total equity attributable to owners of parent company | 1,343,516 | 1,520,192 | 2,319,988 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 7,917 | 15,711 | 51,507 |
| Total Equity | 1,351,433 | 1,535,903 | 2,371,495 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 101,000 | 101,000 | 204,000 |
| Net asset value per share | 14 | 16 | 25 |
